Fig. 6

SAFit2 reduces murine and human macrophage migration in vitro. Primary monocytes were isolated and differentiated into macrophages in vitro. The effect of SAFit2 on macrophage migration was assessed in Transwell assays in which the cells were treated either with different concentrations of SAFit2 or with ddSAFit2 for two hours. Other structurally different FKBP51 inhibitors (19^(S)−Me [26] and cmpd 16 h [41]) were added already 24 h previous the Transwell assays and were kept in medium during the assay. A Representative images of stained membranes displaying reduced murine macrophage migration after SAFit2 treatment. B Quantification of murine macrophage migration after SAFit2 and ddSAFit2 treatment. C Quantification of human macrophage migration after SAFit2 and ddSAFit2 treatment. D Quantification of murine macrophage migration comparing SAFit2 treatment with other unspecific FKBP51 inhibitors. E Quantification of murine macrophage migration comparing unspecific FKBP51 inhibitor treatment with or without additional SAFit2 treatment. The data represent the mean ± SEM of 45–75 quantified images from 9 to 15 membranes per group, which were measured in three runs from 3 to 6 different biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001 one-way ANOVA with Tukey´s post hoc test. cmpd compound, SAFit2 selective antagonist of FKBP51 by induced fit 2